Lipoprotein(a) in the advent of a PCSK9 world

Kotani, Kazuhiko

doi:10.1177/0004563219884965

Cited by 2 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hidenori Arai has received honoraria from Sanofi, Daiichi-Sankyo Co., Ltd., MSD K.K., Kowa Pharmaceutical Co., Ltd., and Pfizer Co., Ltd. Hideaki Bujo has nothing to disclose. Hiroyuki Daida has received honoraria from Amgen Inc., Daiichi-Sankyo Co., Ltd., Kowa Pharmaceutical Co., Ltd., and MSD K.K., and received clinical research funding from Canon Medical Systems Corporation, Philips Japan, Ltd., Toho Holdings Co., Ltd., Asahi Kasei Corporation, and Inter Reha Co., Ltd. HD has also received scholarship grants from Nippon Boehringer Ingelheim Co., Ltd., Otsuka Pharmaceutical Company, Ltd., Sanofi K.K., MSD K.K., Daiichi-Sankyo Co., Ltd., Pfizer Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Astellas Pharma Inc., Takeda Pharmaceutical Co., Ltd., Teijin Pharma, Ltd., Shionogi & Co., Ltd., Actelion Pharmaceuticals, Ltd., at 2-4 years of follow-up although PCSK9 inhibitors that can reduce Lp(a) 38) were not yet used during the study period. To date, evidence of Lp(a)-lowering therapy is scarce prior to the development of PCSK9 inhibitors.…”

Section: Discussionmentioning

confidence: 99%

Relation of Serum Lipoprotein(a) Levels to Lipoprotein and Apolipoprotein Profiles and Atherosclerotic Diseases in Japanese Patients with Heterozygous Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study

Naito

Daida

Masuda

et al. 2022

JAT

View full text Add to dashboard Cite

The official journal of the Japan Atherosclerosis Society and the Asian Pacific Society of Atherosclerosis and Vascular Diseases Original Article Aims: Lipoprotein(a) [Lp(a)] is a plasma lipoprotein consisting of a low-density lipoprotein (LDL)-like particle with apolipoprotein (Apo)(a), attached via a disulfide bond to Apo B100. Previous studies have shown that high Lp(a) levels are associated with an increased risk of cardiovascular disease in patients with familial hypercholesterolemia (FH). To date, limited data are available as to distribution of Lp(a) in FH and associations of Lp(a) with other lipid profiles and cardiovascular disease. Our study aimed to investigate serum Lp(a) levels in relation to other lipid profiles and clinical conditions in the national largest-ever cohort of Japanese FH patients. Methods: This study is a secondary analysis of the Familial Hypercholesterolemia Expert Forum (FAME) Study that includes a Japanese nationwide cohort of FH patients. In 399 patients under treatment for heterozygous FH who had a baseline measurement of serum Lp(a), the present study examined the distribution of Lp(a) levels and associations of Lp(a) with other lipid profiles and clinical conditions including coronary artery disease (CAD). Results: The distribution of Lp(a) was skewed to the right with a median of 20.8 mg/dL, showing a log-normal distribution. Serum Apo B and Apo E levels were positively associated with Lp(a) levels. Age-adjusted mean of Apo B was 8.77 mg/dL higher and that of Apo E was 0.39 mg/dL higher in the highest category (40+ mg/dL) of Lp(a) than in the lowest category ( 20 mg/dL). LDL-C levels did not show such an association with Lp(a) levels. A tendency towards a positive relationship between Lp(a) and prevalent CAD was observed in men. Conclusion: Our study demonstrated a distribution pattern of Lp(a) in Japanese FH patients and positive relationships of Lp(a) with Apo B and Apo E levels.consisting of a low-density lipoprotein (LDL)-like particle with one additional protein, apolipoprotein(a), attached via a disulfide bond to apolipoprotein B100 1) .

show abstract

Section: Discussionmentioning

confidence: 99%

Relation of Serum Lipoprotein(a) Levels to Lipoprotein and Apolipoprotein Profiles and Atherosclerotic Diseases in Japanese Patients with Heterozygous Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study

Naito

Daida

Masuda

et al. 2022

JAT

View full text Add to dashboard Cite

show abstract

“…Whether or not the statin effects influence the relative risk for CVD with Lp(a) in FH subjects is unclear. Recently, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been used to treat high LDL-C levels in conditions such as FH, and these inhibitors reduce not only LDL-C but also Lp(a) levels [ 30 ]. The effect of reduction of Lp(a) by intervention with PCSK9 inhibitors on the relationship between Lp(a) and CVD should be explored in the future.…”

Section: Discussionmentioning

confidence: 99%

Risk of cardiovascular disease with lipoprotein(a) in familial hypercholesterolemia: a review

Watanabe¹,

Hamasaki²,

Kotani³

2020

Arch Med Sci Atheroscler Dis

View full text Add to dashboard Cite

Introduction Lipoprotein(a) (Lp[a]) is a risk factor of cardiovascular disease (CVD). Familial hypercholesterolemia (FH), which exhibits high low-density lipoprotein cholesterol (LDL-C) levels, is a risk factor of CVD. The relationship of Lp(a) with CVD has been characterized in populations specific to FH. Material and methods Studies reporting on the relationship of Lp(a) with CVD among FH subjects via PubMed up to 2020 were reviewed. Results Eight studies were identified as eligible. In the meta-analyses, a high Lp(a) level was significantly and predictively associated with CVD compared to a low Lp(a) level in 2 cross-sectional studies (odds ratio = 2.57; 95% confidence interval (CI): 1.16–5.73) and 6 cohort studies (risk/hazard ratio = 1.91; 95% CI: 1.50–2.43). The totally integrated relative risk of these studies was 1.97 (95% CI: 1.57–2.46). Conclusions FH subjects with high Lp(a) levels can have a high CVD risk, and besides LDL-C, attention should be paid to Lp(a) levels in FH subjects.

show abstract

Lipoprotein(a) in the advent of a PCSK9 world

Cited by 2 publications

References 5 publications

Relation of Serum Lipoprotein(a) Levels to Lipoprotein and Apolipoprotein Profiles and Atherosclerotic Diseases in Japanese Patients with Heterozygous Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study

Relation of Serum Lipoprotein(a) Levels to Lipoprotein and Apolipoprotein Profiles and Atherosclerotic Diseases in Japanese Patients with Heterozygous Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study

Risk of cardiovascular disease with lipoprotein(a) in familial hypercholesterolemia: a review

Contact Info

Product

Resources

About